Evaluation of the safety and brain-related tissues distribution characteristics of TAT-HaFGF via intranasal administration

Biological and Pharmaceutical Bulletin

Volumn 37, Issue 7, 2014, Pages 1149-1157

  Xu, Jinmei ^a   Xiang, Qi ^a   Su, Junhui ^a   Yang, Penghui ^a   Zhang, Qihao ^a   Su, Zhijian ^a   Xiao, Fei ^b   Huang, Yadong ^a  

^a JINAN UNIVERSITY   (China)

^b MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

Author keywords

Intranasal administration; Mucosal adsorption; Safety evaluation; TAT human acidic fibroblast

Indexed keywords

ARGININE; EOSIN; HEMATOXYLIN; HYBRID PROTEIN; LYSINE; NEUROPROTECTIVE AGENT; OLFACTORY MARKER PROTEIN; TAT HUMAN ACIDIC FIBROBLAST GROWTH FACTOR; UNCLASSIFIED DRUG; FIBROBLAST GROWTH FACTOR; TAT-HAFGF (19-154); TRANSACTIVATOR PROTEIN;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BUFO BUFO; CONTROLLED STUDY; CYTOTOXICITY TEST; DOSE RESPONSE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG SAFETY; DRUG SCREENING; DRUG TISSUE LEVEL; FEMALE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; ISOTOPE TRACING; MALE; NONHUMAN; NOSE MUCOSA; OLFACTORY BULB; PROTEIN EXPRESSION; RADIOACTIVITY; RAT; SENSORY NERVE CELL; ANIMAL; BRAIN; DRUG EFFECTS; EUKARYOTIC FLAGELLUM; INTRANASAL DRUG ADMINISTRATION; METABOLISM; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION;

ADMINISTRATION, INTRANASAL; ANIMALS; BRAIN; BUFO BUFO; CILIA; FEMALE; FIBROBLAST GROWTH FACTORS; GENE PRODUCTS, TAT; MALE; NASAL ABSORPTION; NASAL MUCOSA; NEUROPROTECTIVE AGENTS; OLFACTORY BULB; RATS, SPRAGUE-DAWLEY; RECOMBINANT FUSION PROTEINS; SENSORY RECEPTOR CELLS; TISSUE DISTRIBUTION;

EID: 84904597257     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b14-00023     Document Type: Article

References (41)

1. Vaka SR, Sammeta SM, Day LB, Murthy SN. Delivery of nerve growth factor to brain via intranasal administration and enhancement of brain uptake. J. Pharm. Sci., 98, 3640-3646 (2009).
2. Lv Q, Fan X, Xu G, Liu Q, Tian L, Cai X, Sun W, Wang X, Cai Q, Bao Y, Zhou L, Zhang Y, Ge L, Guo R, Liu X. Intranasal delivery of nerve growth factor attenuates aquaporins-4-induced edema following traumatic brain injury in rats. Brain Res., 1493, 80-89 (2013).
3. Prediger RD, Aguiar AS Jr, Matheus FC, Walz R, Antoury L, Raisman-Vozari R, Doty RL. Intranasal administration of neurotoxicants in animals: support for the olfactory vector hypothesis of Parkinson's disease. Neurotox. Res., 21, 90-116 (2012).
4. Hanson LR, Frey WH 2nd Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci., 9 (Suppl. 3), S5 (2008).
5. Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, Green PS, Leverenz J, Cross D, Gerton B. Intranasal insulin therapy for Alzheimer's disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch. Neurol., 69, 29-38 (2012).
6. Chen XQ, Fawcett JR, Rahman YE, Ala TA, Frey IW II. Delivery of nerve growth factor to the brain via the olfactory pathway. Journal of Alzheimer's disease: JAD, 1, 35-44 (1998).
7. Dhuria SV, Hanson LR, Frey WH 2nd Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system. J. Pharm. Sci., 98, 2501-2515 (2009).
8. Nonaka N, Farr SA, Kageyama H, Shioda S, Banks WA. Delivery of galanin-like peptide to the brain: targeting with intranasal delivery and cyclodextrins. J. Pharmacol. Exp. Ther., 325, 513-519 (2008).
9. Thorne RG, Pronk GJ, Padmanabhan V, Frey WH 2nd Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience, 127, 481-496 (2004).
10. Francis GJ, Martinez JA, Liu WQ, Xu K, Ayer A, Fine J, Tuor UI, Glazner G, Hanson LR, Frey WH 2nd, Toth C. Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy. Brain, 131, 3311-3334 (2008).
11. Ross TM, Martinez PM, Renner JC, Thorne RG, Hanson LR, Frey WH 2nd Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: a non-invasive treatment strategy for multiple sclerosis. J. Neuroimmunol., 151, 66-77 (2004).
12. Ma YP, Ma MM, Ge S, Guo RB, Zhang HJ, Frey WH 2nd, Xu GL, Liu XF. Intranasally delivered TGF-beta1 enters brain and regulates gene expressions of its receptors in rats. Brain Res. Bull., 74, 271-277 (2007).
13. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat. Rev. Drug Discov., 8, 235-253 (2009).
14. Kass MD, Moberly AH, McGann JP. Spatiotemporal alterations in primary odorant representations in olfactory marker protein knockout mice. PLoS ONE, 8, e61431 (2013).
15. Xia H, Mao Q, Davidson BL. The HIV Tat protein transduction domain improves the biodistribution of beta-glucuronidase expressed from recombinant viral vectors. Nat. Biotechnol., 19, 640-644 (2001).
16. Cecchelli R, Berezowski V, Lundquist S, Culot M, Renftel M, Dehouck MP, Fenart L. Modelling of the blood-brain barrier in drug discovery and development. Nat. Rev. Drug Discov., 6, 650-661 (2007).
17. Cooper I, Sasson K, Teichberg VI, Schnaider-Beeri M, Fridkin M, Shechter Y. Peptide derived from HIV-1 TAT protein destabilizes a monolayer of endothelial cells in an in vitro model of the blood-brain barrier and allows permeation of high molecular weight proteins. J. Biol. Chem., 287, 44676-44683 (2012).
18. Santra S, Yang H, Stanley JT, Holloway PH, Moudgil BM, Walter G, Mericle RA. Rapid and effective labeling of brain tissue using TAT-conjugated CdS : Mn/ZnS quantum dots. Chem. Commun. (Camb.), 2005, 3144-3146 (2005).
19. Wang Y, Lin H, Lin S, Qu J, Xiao J, Huang Y, Xiao Y, Fu X, Yang Y, Li X. Cell-penetrating peptide TAT-mediated delivery of acidic FGF to retina and protection against ischemia-reperfusion injury in rats. J. Cell. Mol. Med., 14, 1998-2005 (2010).
20. Ionescu IA, Dine J, Yen Y-C, Buell DR, Herrmann L, Holsboer F, Eder M, Landgraf R, Schmidt U. Intranasally administered neuropeptide S (NPS) exerts anxiolytic effects following internalization into NPS receptor-expressing neurons. Neuropsychopharmacology, 37, 1323-1337 (2012).
21. 14-154 attenuates disease progression in a mouse model of Alzheimer's disease. Neuroscience, 223, 225-237 (2012).
22. Huang Y, Rao Y, Feng C, Li Y, Wu X, Su Z, Xiao J, Xiao Y, Feng W, Li X. High-level expression and purification of Tat-haFGF19-154. Appl. Microbiol. Biotechnol., 77, 1015-1022 (2008).
23. Gao X, Tao W, Lu W, Zhang Q, Zhang Y, Jiang X, Fu S. Lectin-conjugated PEG-PLA nanoparticles: preparation and brain delivery after intranasal administration. Biomaterials, 27, 3482-3490 (2006).
24. Capsoni S, Giannotta S, Cattaneo A. Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in antinerve growth factor mice. Proc. Natl. Acad. Sci. U.S.A., 99, 12432-12437 (2002).
25. Marks DR, Tucker K, Cavallin MA, Mast TG, Fadool DA. Awake intranasal insulin delivery modifies protein complexes and alters memory, anxiety, and olfactory behaviors. J. Neurosci., 29, 6734-6751 (2009).
26. Tang YM, Yang SF, Zhu B, Cui JS. Therapeutic effects of recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand on non-small lung cell cancer: an experimental with rats. Zhonghua Yi Xue Za Zhi, 85, 2021-2025 (2005).
27. Lin YL, Kuo HS, Lo MJ, Tsai MJ, Lee MJ, Huang WC, Kuo WC, Shih YH, Cheng H, Huang MC. Treatment with nerve grafts and aFGF attenuates allodynia caused by cervical root transection injuries. Restor. Neurol. Neurosci., 29, 265-274 (2011).
28. Bohnen NI, Muller ML. In vivo neurochemical imaging of olfactory dysfunction in Parkinson's disease. J. Neural Transm., 120, 571-576 (2013).
29. Djordjevic J, Jones-Gotman M, De Sousa K, Chertkow H. Olfaction in patients with mild cognitive impairment and Alzheimer's disease. Neurobiol. Aging, 29, 693-706 (2008).
30. Aebischer P, Ridet J. Recombinant proteins for neurodegenerative diseases: the delivery issue. Trends Neurosci., 24, 533-540 (2001).
31. Renner DB, Frey WH 2nd, Hanson LR. Intranasal delivery of siRNA to the olfactory bulbs of mice via the olfactory nerve pathway. Neurosci. Lett., 513, 193-197 (2012).
32. John JA, Key B. Axon mis-targeting in the olfactory bulb during regeneration of olfactory neuroepithelium. Chem. Senses, 28, 773-779 (2003).
33. Williams SK, Franklin RJ, Barnett SC. Response of olfactory ensheathing cells to the degeneration and regeneration of the peripheral olfactory system and the involvement of the neuregulins. J. Comp. Neurol., 470, 50-62 (2004).
34. Karceski S. Trigeminal nerve stimulator: a new treatment for seizures? Neurology, 80, e95-e97 (2013).
35. Cushman M, Johnson BS, King OD, Gitler AD, Shorter J. Prionlike disorders: blurring the divide between transmissibility and infectivity. J. Cell Sci., 123, 1191-1201 (2010).
36. Naudin M, Mondon K, Atanasova B. Alzheimer's disease and olfaction. Geriatrie et Psychologie Neuropsychiatrie du Vieillissement, 11, 287-293 (2013).
37. Seligman SC, Kamath V, Giovannetti T, Arnold SE, Moberg PJ. Olfaction and apathy in Alzheimer's disease, mild cognitive impairment, and healthy older adults. Aging Ment. Health, 17, 564-570 (2013).
38. Wesson DW, Levy E, Nixon RA, Wilson DA. Olfactory dysfunction correlates with amyloid-beta burden in an Alzheimer's disease mouse model. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience, 30, 505-514 (2010).
39. Cao L, Schrank BR, Rodriguez S, Benz EG, Moulia TW, Rickenbacher GT, Gomez AC, Levites Y, Edwards SR, Golde TE, Hyman BT, Barnea G, Albers MW. Abeta alters the connectivity of olfactory neurons in the absence of amyloid plaques in vivo. Nat. Commun., 3, 1009 (2012).
40. Zhang L, Fang Y, Zeng Z, Lian Y, Wei J, Zhu H, Jia Y, Zhao X, Xu Y. BDNF gene polymorphisms are associated with Alzheimer's disease-related depression and antidepressant response. Journal of Alzheimer's Disease: JAD, 26, 523-530 (2011).
41. Mandel RJ. CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease. Curr. Opin. Mol. Ther., 12, 240-247 (2010).